Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2014Clinical Cancer Research

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAndrew P. GarnerAstraZeneca (United Kingdom)JGJoseph M. GozgitAkebia Therapeutics (United States)RARana AnjumTE Laboratories (Ireland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Garner et al. (2014) studied this question.

synapsesocial.com/papers/6a952efd25f7ee1b823310e8https://doi.org/10.1158/1078-0432.ccr-14-1397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors1998 · 4,512 citations
  2. 2Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors2006 · 819 citations
  3. 3Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias2012 · 780 citations
  4. 4KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients2009 · 401 citations
  5. 5PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors2003 · 2,310 citations